The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in December.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in 2025, with results expected in Q1.

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous expectation to file towards end-2025.